Citadel Advisors
ZYME icon

Citadel Advisors’s Zymeworks ZYME Stock Holding History

Citadel Advisors’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$336K Sell
13,400
-17,200
-56% -$407K ﹤0.01% 10220
2025
Q4 		$806K Buy
+30,600
New +$667K ﹤0.01% 7903
2025
Q3 		– Sell
-12,900
Closed -$162K – 14334
2025
Q2 		$162K Sell
12,900
-700
-5% -$8.34K ﹤0.01% 10887
2025
Q1 		$162K Buy
13,600
+7,100
+109% +$96.8K ﹤0.01% 10748
2024
Q4 		$95.2K Sell
6,500
-3,800
-37% -$53.1K ﹤0.01% 11555
2024
Q3 		$129K Buy
10,300
+1,900
+23% +$20.7K ﹤0.01% 10770
2024
Q2 		$71.5K Sell
8,400
-2,700
-24% -$24K ﹤0.01% 11354
2024
Q1 		$117K Buy
11,100
+4,300
+63% +$47.7K ﹤0.01% 11141
2023
Q4 		$70.7K Sell
6,800
-2,200
-24% -$17.5K ﹤0.01% 11379
2023
Q3 		$57.1K Sell
9,000
-18,300
-67% -$135K ﹤0.01% 11594
2023
Q2 		$236K Buy
27,300
+11,500
+73% +$103K ﹤0.01% 9526
2023
Q1 		$143K Sell
15,800
-17,500
-53% -$153K ﹤0.01% 10722
2022
Q4 		$262K Buy
+33,300
New +$234K ﹤0.01% 9610
2022
Q2 		– Sell
-26,000
Closed -$170K – 14276
2022
Q1 		$170K Buy
26,000
+5,300
+26% +$47.2K ﹤0.01% 11708
2021
Q4 		$339K Sell
20,700
-1,900
-8% -$39.6K ﹤0.01% 10657
2021
Q3 		$656K Sell
22,600
-7,100
-24% -$236K ﹤0.01% 9228
2021
Q2 		$1.03M Sell
29,700
-4,000
-12% -$127K ﹤0.01% 8294
2021
Q1 		$1.06M Buy
33,700
+16,200
+93% +$658K ﹤0.01% 7960
2020
Q4 		$827K Buy
17,500
+11,500
+192% +$534K ﹤0.01% 7189
2020
Q3 		$279K Sell
6,000
-12,400
-67% -$426K ﹤0.01% 8251
2020
Q2 		$664K Sell
18,400
-6,000
-25% -$221K ﹤0.01% 6568
2020
Q1 		$865K Buy
24,400
+13,700
+128% +$561K ﹤0.01% 5588
2019
Q4 		$486K Buy
+10,700
New +$389K ﹤0.01% 6845

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Citadel Advisors's ZYME Position: Q1 2026 in Review

Citadel Advisors increased its Zymeworks (ZYME) stake by 350% in Q1 2026, buying an estimated $21.2M and bringing the position to 1,150,018 shares worth $28.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1907.

Citadel Advisors first reported a position in ZYME in Q4 2017 and has held it in 30 quarters since. The position peaked at $33.1M in Q2 2020. 211 funds tracked by Wall St. Rank hold ZYME as of Q1 2026.

  • Citadel Advisors held 1,150,018 shares of Zymeworks worth $28.8M as of Q1 2026.
  • Citadel Advisors bought 894,667 Zymeworks shares in Q1 2026, an estimated $21.2M.
  • Zymeworks made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #1907 holding.
  • Citadel Advisors first reported a position in Zymeworks in Q4 2017 and has held it in 30 quarters since.
  • Citadel Advisors's Zymeworks position peaked at $33.1M in Q2 2020.
  • 211 funds tracked by Wall St. Rank held Zymeworks as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.